pediatric cancer research

Childhood Cancer Genomics Gaps

NCI convened a workshop February 4-5, 2015, of representative research teams that have been leaders in defining the genomic landscape of childhood cancers to discuss the influence of genomic discoveries on the future of childhood cancer research.

Workshop participants also included clinical researchers, members of regulatory agencies, and members of the childhood cancer research advocacy community. The participants are listed at the end of this document.

The workshop focused on the identification of gaps in current understanding and opportunities for future research.

Workshop participants identified the following research gaps and opportunities as areas that warrant future research focus:

  • Continued discovery research to more comprehensively characterize the genomic and epigenomic alterations that are present in childhood cancers and their clinically relevant subsets
  • Clinical research protocols focused on identifying the genomic landscape of childhood cancers at relapse and on evaluating therapeutic strategies for genomically-defined patient subsets at relapse
  • A childhood cancer Genomic Data Commons to facilitate collaboration across research teams and to facilitate the identification and clinical relevance of low-frequency genomic alterations
  • Preclinical models that faithfully replicate the relevant genomic alterations of childhood cancers
  • Identification of treatments to directly or indirectly target pediatric cancer driver genomic alterations for which there are currently no available targeted agents, including the fusion genes that characterize selected pediatric sarcomas (e.g., Ewing sarcoma, synovial sarcoma, and alveolar rhabdomyosarcoma) and childhood leukemias, the mutated histones found in pediatric high-grade gliomas, and the SMARCB1 alterations found in rhabdoid tumors
  • Further definition of germline dominant and recessive lesions that predispose to cancer and the maintenance of this information within accessible databases, and the enhancement of the genetic counseling capabilities of institutions that treat children with cancer

 

Specific objectives of the workshop included identifying new opportunities created by molecular studies that might allow more effective diagnosis and treatment of childhood cancers.

Clinical translation of genomic discoveries for childhood cancers was also discussed. The text that follows summarizes the key issues addressed at the workshop and focuses on the future research directions highlighted by workshop participants

The summary is provided to inform the childhood cancer community about important areas that warrant further research investment.

 

Read the complete report....

 

 

National Cancer Institute (www.cancer.gov


Dr. Mark Souweidane: Diffuse Pontine Intrinsic Glioma (DPIG)

 

ARSE UPDATE (Advancement of Research & Scientific Exchange): LuciaGirl's neurosurgeon is participating in an...

Posted by Lucia Girl Pediatric Oncology Foundation - LGPOF on Tuesday, July 28, 2015

Diffuse intrinsic pontine glioma: poised for progress. 

Abstract

Diffuse intrinsic pontine gliomas (DIPGs) are amongst the most challenging tumors to treat. Surgery is not an option, the effects of radiation therapy are temporary, and no chemotherapeutic agent has demonstrated significant efficacy.

Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, yet without success.

The diagnosis of DIPG is based on radiographic findings in the setting of a typical clinical presentation, and tissue is not routinely obtained as the standard of care. The paradigm for treating children with these tumors has been based on that for supratentorial high-grade gliomas in adults as the biology of these lesions were presumed to be similar. However, recent pivotal studies demonstrate that DIPGs appear to be their own entity.

Simply identifying this fact releases a number of constraints and opens opportunities for biologic investigation of these lesions, setting the stage to move forward in identifying DIPG-specific treatments. This review will summarize the current state of knowledge of DIPG, discuss obstacles to therapy, and summarize results of recent biologic studies. Full Text...

Warren, Katherine E. “Diffuse Intrinsic Pontine Glioma: Poised for Progress.” Frontiers in Oncology 2 (2012): 205. PMC. Web. 21 Aug. 2015.